American Journal of Cardiology
Volume 101, Issue 8, Supplement , Pages S14-S19 , 17 April 2008

Niacin Use and Cutaneous Flushing: Mechanisms and Strategies for Prevention

  • Michael H. Davidson, MD

      Affiliations

    • Corresponding Author InformationAddress for reprints: Michael H. Davidson, MD, University of Chicago, Pritzker School of Medicine, 515 North State Street, Suite 2700, Chicago, Illinois 60610-4310.

References 

  1. Canner PL, Berge KG, Wenger NK, Stamler J, Friedman L, Prineas RJ, et al. Fifteen year mortality in coronary drug project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986;8:1245–1255
  2. Guyton JR, Bays HE. Safety considerations with niacin therapy. Am J Cardiol. 2007;99(suppl):22C–31C
  3. Birjmohun RS, Kastelein JJ, Poldermans D, Stroes ES, Hostalek U, Assmann G. Safety and tolerability of prolonged-release nicotinic acid in statin-treated patients. Curr Med Res Opin. 2007;23:1707–1713
  4. Carlson LA. Nicotinic acid: the broad-spectrum lipid drug (A 50th anniversary review). J Intern Med. 2005;258:94–114
  5. Spies TD, Cooper C, Blankenhorm MA. The use of nicotinic acid in the treatment of pellagra. JAMA. 1938;110:622–627
  6. Goldsmith GA, Cordill S. The vasodilating effects of nicotinic acid. Am J Med Sci. 1943;205:204–208
  7. Svedmyr N, Harthon L, Lundholm L. The relationship between the plasma concentration of free nicotinic acid and some of its pharmacologic effects in man. Clin Pharmacol Ther. 1969;10:559–570
  8. Aberg G, Svedmyr N. Thermographic registration of flush. Arzneimittelforschung. 1971;21:795–796
  9. Morrow JD, Awad JA, Oates JA, Roberts LJ. Identification of skin as a major site of prostaglandin D2 release following oral administration of niacin in humans. J Invest Dermatol. 1992;98:812–815
  10. Cheng K, Wu TJ, Wu KK, Sturino C, Metters K, Gottesdiener K, et al. Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. Proc Natl Acad Sci U S A. 2006;103:6682–6687
  11. Saareks V, Mucha I, Sievi E, Riutta A. Nicotinic acid and pyridoxine modulate arachidonic acid metabolism in vitro and ex vivo in man. Pharmacol Toxicol. 1999;84:274–280
  12. Benyó Z, Gille A, Bennett CL, Clausen BE, Offermanns S. Nicotinic acid-induced flushing is mediated by activation of epidermal Langerhans cells. Mol Pharmacol. 2006;70:1844–1849
  13. Guyton JR. Niacin in cardiovascular prevention: mechanisms, efficacy, and safety. Curr Opin Lipidol. 2007;18:415–420
  14. Morrow JD, Parsons WG, Roberts LJ. Release of markedly increased quantities of prostaglandin D2 in vivo in humans following the administration of nicotinic acid. Prostaglandins. 1989;38:263–274
  15. Benyó Z, Gille A, Kero J, Csiky M, Suchánková MC, Nüsing RM, et al. GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing. J Clin Invest. 2005;115:3634–3640
  16. Pike NB. Flushing out the role of GPR109A (HM74A) in the clinical efficacy of nicotinic acid. J Clin Invest. 2005;115:3400–3403
  17. Meyers CD, Carr MC, Park S, Brunzell JD. Varying cost and free nicotinic acid content in over-the-counter niacin preparations for dyslipidemia. Ann Intern Med. 2003;139:996–1002
  18. Stern RH, Spence JD, Freeman DJ, Parbtani A. Tolerance to nicotinic acid flushing. Clin Pharmacol Ther. 1991;50:66–70
  19. Cefali EA, Simmons PD, Stanek EJ, Shamp TR. Improved control of niacin-induced flushing using an optimized once-daily, extended-release niacin formulation. Int J Clin Pharmacol Ther. 2006;44:633–640
  20. Ballantyne CM, Davidson MH, McKenney J, Keller LH, Bajorunas DR, Karas RH. Comparison of the efficacy and safety of a combination tablet of niacin extended-release and simvastatin and simvastatin monotherapy: the SEACOST I (high-dose) study. Am J Cardiol. In press.
  21. Ballantyne CM, Davidson MH, McKenney J, Keller LH, Bajorunas DR, Karas RH. Comparison of the efficacy and safety of a combination tablet of niacin extended-release and simvastatin with simvastatin 80 mg monotherapy: the SEACOST II (high-dose) study. J Clin Lipidol. In press.
  22. Karas RH, Kashyap M, Knopp R, Keller LH, Bajorunas DR, Davidson MH. Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study. Am J Cardiovasc Drugs. 2008;2:69–81
  23. McKenney J. New perspectives on the use of niacin in the treatment of lipid disorders. Arch Intern Med. 2004;164:697–705
  24. Abbott Laboratories. Niaspan tablets: niacin extended-release tablets. Available at: http://www.rxabbott.com/pdf/niaspan.pdf. Accessed November 20, 2007.
  25. Capuzzi DM, Guyton JR, Morgan JM, Goldberg AC, Kreisberg RA, Brusco OA, et al. Efficacy and safety of an extended-release niacin (Niaspan): a long-term study. Am J Cardiol. 1998;82(suppl):74U–81U
  26. Rubenfire M the Impact of Medical Subspecialty on Patient Compliance to Treatment Study Group. Safety and compliance with once-daily niacin extended-release/lovastatin as initial therapy in the Impact of Medical Subspecialty on Patient Compliance to Treatment (IMPACT) study. Am J Cardiol. 2004;94:306–311
  27. Cefali EA, Simmons PD, Stanek EJ, McGovern ME, Kissling CJ. Aspirin reduces cutaneous flushing after administration of an optimized extended-release niacin formulation. Int J Clin Pharmacol Ther. 2007;45:78–88
  28. Dunn RT, Ford MA, Rindone JP, Kwiecinski FA. Low-dose aspirin and ibuprofen reduce the cutaneous reactions following niacin administration. Am J Ther. 1995;2:478–480
  29. Whelan AM, Price SO, Fowler SF, Hainer BL. The effect of aspirin on niacin-induced cutaneous reactions. J Fam Pract. 1992;34:165–168
  30. Wilkin JK, Wilkin O, Kapp R, Donachie R, Chernosky ME, Buckner J. Aspirin blocks nicotinic acid-induced flushing. Clin Pharamacol Ther. 1982;31:478–482
  31. Jungnickel PW, Maloley PA, Vander Tuin EL, Peddicord TE, Campbell JR. Effect of two aspirin pretreatment regimens on niacin-induced cutaneous reactions. J Gen Intern Med. 1997;12:591–596
  32. Oberwittler H, Baccara-Dinet M. Clinical evidence for use of acetyl salicylic acid in control of flushing related to nicotinic acid treatment. Int J Clin Pract. 2006;60:707–715
  33. Knopp RH. Evaluating niacin in its various forms. Am J Cardiol. 2000;86(suppl):51L–56L

 Statement of author disclosure: Please see the Author Disclosures section at the end of this article.

PII: S0002-9149(08)00252-X

doi: 10.1016/j.amjcard.2008.02.028

American Journal of Cardiology
Volume 101, Issue 8, Supplement , Pages S14-S19 , 17 April 2008

Article Tools

* Image Usage & Resolution